News | November 15, 2022
SMS Pharma revenue down 9%
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Results reinforce commitment to next-generation oral SERD development programme
‘PathoDetect HPV Detection Test’ detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers.
Transformation to pure-play Innovative Medicines company nears completion
Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Subscribe To Our Newsletter & Stay Updated
